Published in Curr Opin Lipidol on December 01, 2003
PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J Clin Invest (2005) 1.49
Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag (2008) 1.10
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation (2011) 0.97
Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag (2007) 0.89
The BUGS project: Evolution, critique and future directions. Stat Med (2009) 11.19
Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet (2010) 8.27
Immediate benefits realized following implementation of physician order entry at an academic medical center. J Am Med Inform Assoc (2002) 3.32
Key attributes of a successful physician order entry system implementation in a multi-hospital environment. J Am Med Inform Assoc (2001) 2.54
The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care (2012) 2.33
The impending shortage and the estimated cost of training the future surgical workforce. Ann Surg (2009) 1.90
Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn (2002) 1.89
Toward acquiring comprehensive radiosurgery field commissioning data using the PRESAGE/optical-CT 3D dosimetry system. Phys Med Biol (2010) 1.85
Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab (2013) 1.83
Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J Clin Invest (2007) 1.73
A sensitive LC/MS/MS assay of 25OH vitamin D3 and 25OH vitamin D2 in dried blood spots. Clin Chim Acta (2009) 1.39
Commissioning a small-field biological irradiator using point, 2D, and 3D dosimetry techniques. Med Phys (2011) 1.35
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf (2002) 1.24
A quality assurance method that utilizes 3D dosimetry and facilitates clinical interpretation. Int J Radiat Oncol Biol Phys (2012) 1.19
Quantification of normal cell fraction and copy number neutral LOH in clinical lung cancer samples using SNP array data. PLoS One (2009) 1.14
Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab (2003) 1.11
Low-intensity exercise exerts beneficial effects on plasma lipids via PPARgamma. Med Sci Sports Exerc (2008) 1.10
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther (2009) 1.09
What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab (2012) 1.02
Commissioning and dosimetric characteristics of TrueBeam system: composite data of three TrueBeam machines. Med Phys (2012) 1.02
Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus. Am J Hypertens (2005) 1.00
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs (2004) 0.96
The myotoxicity of statins. Curr Opin Lipidol (2002) 0.96
Postprandial glucose - a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol (2009) 0.95
Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol (2011) 0.94
Validation of a novel cognitive bias task based on difference in quantity of reinforcement for assessing environmental enrichment. Anim Cogn (2013) 0.92
Bayesian hierarchical model for correcting signal saturation in microarrays using pixel intensities. Stat Appl Genet Mol Biol (2006) 0.91
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. Pharmacoeconomics (2006) 0.90
Differences in diagnosis and treatment using telemedicine versus in-person evaluation of acute illness. Ambul Pediatr (2006) 0.89
Effectiveness of telemedicine in replacing in-person evaluation for acute childhood illness in office settings. Telemed J E Health (2006) 0.87
Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Prefer Adherence (2013) 0.85
Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol (2010) 0.85
Neonatal biochemical screening for disease. Clin Chim Acta (2002) 0.85
The impact of treatment non-compliance on mortality in people with type 1 diabetes. J Diabetes Complications (2012) 0.84
An investigation into a new re-useable 3D radiochromic dosimetry material, Presage. J Phys Conf Ser (2010) 0.84
Pioglitazone in clinical practice: where are we now? Diabetes Ther (2012) 0.82
The metabolic syndrome, inflammation and cardiovascular disease in type 2 diabetes. Curr Opin Lipidol (2004) 0.82
Familial hypercholesterolaemia: underdiagnosed and undertreated. Eur Heart J (2008) 0.82
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. J Nutr Metab (2012) 0.81
Beam-specific planning target volumes incorporating 4D CT for pencil beam scanning proton therapy of thoracic tumors. J Appl Clin Med Phys (2015) 0.81
Bayesian hierarchical model for estimating gene expression intensity using multiple scanned microarrays. EURASIP J Bioinform Syst Biol (2008) 0.81
Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database. Atherosclerosis (2009) 0.81
Prevalence of mutations leading to complete C6 deficiency (C6Q0) in the Western Cape, South Africa and detection of novel mutations leading to C6Q0 in an Irish family. Mol Immunol (2007) 0.81
Association of pathogen strain-specific gene transcription and transmission efficiency phenotype of Anaplasma marginale. Infect Immun (2010) 0.81
Use of intense pulsed light and a retinyl-based cream as a potential treatment for cellulite: a pilot study. J Cosmet Dermatol (2006) 0.80
Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes. PLoS One (2011) 0.80
The PPAR-gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium. Biochem Biophys Res Commun (2005) 0.80
Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia. Am J Cardiovasc Drugs (2011) 0.79
The future direction of cholesterol-lowering therapy. Curr Opin Lipidol (2002) 0.79
NAADP regulates human platelet function. Biochem J (2012) 0.78
Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study. Clin Ther (2011) 0.77
Total lipid management and residual risk: beyond statin therapy. Br J Hosp Med (Lond) (2011) 0.77
Incidental findings of CSF leakage in patients without spontaneous intracranial hypotension and development of post-dural puncture headache. Eur Radiol (2013) 0.77
Surface characterization of SLActive dental implants. Eur J Esthet Dent (2012) 0.77
A rare complication with a single dose of alendronate. BMJ Case Rep (2010) 0.77
Evidence for use of fibrates in diabetic dyslipidemia: are we looking hard enough? Curr Opin Lipidol (2011) 0.77
Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes. Diab Vasc Dis Res (2005) 0.76
Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom. Diabetes Ther (2013) 0.76
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes. Diabetes Ther (2014) 0.75
Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. Adv Ther (2014) 0.75
Full likelihood analysis of genetic risk with variable age at onset disease--combining population-based registry data and demographic information. PLoS One (2009) 0.75
Inhibition of PCSK9: is this the way forward for managing residual risk? Curr Opin Lipidol (2012) 0.75
Therapy and clinical trials: nicotinic acid in the management of atherosclerotic disease. Curr Opin Lipidol (2010) 0.75
Submerged RadBall® deployments in Hanford Site hot cells containing 137CsCl capsules. Health Phys (2012) 0.75
Rejoinder to commentaries on 'The BUGS project: Evolution, critique and future directions'. Stat Med (2009) 0.75
Short-term cost cutting is not the answer. Br J Hosp Med (Lond) (2008) 0.75
Therapy and clinic trials. Curr Opin Lipidol (2007) 0.75
Therapy and clinical trials -- coronary heart disease: current and future perspectives. Curr Opin Lipidol (2003) 0.75
Care assistant regulation would help improve care home quality. Nurs Stand (2014) 0.75
Locating radiation hazards and sources within contaminated areas by implementing a reverse ray tracing technique in the RadBall™ technology. Health Phys (2012) 0.75
PEGylation of nanosubstrates (titania) with multifunctional reagents: at the crossroads between nanoparticles and nanocomposites. Langmuir (2012) 0.75
Therapy and clinical trials: metabolic syndrome and cardiovascular risk management. Curr Opin Lipidol (2008) 0.75
A potential role for monoclonal antibodies in clinical lipidology: can we look beyond statins? Curr Opin Lipidol (2013) 0.75
Multitechnique characterization of CPTi surfaces after electro discharge machining (EDM). Clin Oral Investig (2013) 0.75
Dietary goal attainment measures and psychosocial factors among Mexican Americans and non-Hispanic whites with type 2 diabetes. Ecol Food Nutr (2012) 0.75
Apolipoprotein B: can we continue to ignore? Curr Opin Lipidol (2010) 0.75
Novel cardiovascular risk-assessment metrics and absolute risk assessment: future role in clinical practice? Curr Opin Lipidol (2014) 0.75
Estimation of cardiovascular risk using 10-year risk metric: time for a rethink? Curr Opin Lipidol (2012) 0.75
Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition: issues with efficacy, tolerability and safety. Curr Opin Lipidol (2014) 0.75
Hip abductor re-attachment audited using a wire marker. Acta Orthop Belg (2011) 0.75
Bariatric surgery and cardiovascular risk reduction. Curr Opin Lipidol (2014) 0.75
Therapy and clinical trials: glycaemic control and cardiovascular disease. Curr Opin Lipidol (2009) 0.75
Therapy and clinical trials: type 2 diabetes: lifestyle and beyond. Curr Opin Lipidol (2002) 0.75
The onward march of PCSK9 inhibition. Curr Opin Lipidol (2017) 0.75
Do the mechanisms by which LDL-c levels are reduced influence the extent of clinical benefit which subsequently accrues? Curr Opin Lipidol (2016) 0.75
In defence of obsolete data. QJM (2010) 0.75
Therapy and clinical trials: Familial hypercholesterolaemia and prevention of coronary artery disease. Curr Opin Lipidol (2009) 0.75
Statin/ezetimibe combination therapy: emerging evidence. Curr Opin Lipidol (2011) 0.75
Nutrition and metabolism. Curr Opin Lipidol (2008) 0.75
Diabetes and cardiovascular disease: new perspectives. Curr Opin Lipidol (2009) 0.75
Atherosclerosis and lipoproteins: vascular cell senescence and atherosclerosis. Curr Opin Lipidol (2007) 0.75
Management of homozygous familial hypercholesterolaemia. Curr Opin Lipidol (2014) 0.75
Microsomal triglyceride transfer protein inhibition: a novel treatment for lowering plasma cholesterol. Curr Opin Lipidol (2014) 0.75